Cue Biopharma, Inc. (CUE) Stock Price

CUEStock

$16.71−29.49%52W

Market Cap$121.39M

P/E—

PEG Ratio—

Div yield—

Beta2.86

CUE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)17.26%

Price vs S&P 500 (4W)-39.57%

VGM Score56.72

Book Value / Share (Quarterly)$0.44

P/TBV (Annual)3.15x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)180.09%

Cash Flow / Share (Quarterly)$-9.59

Price vs S&P 500 (YTD)70.70%

Net Profit Margin (TTM)-435.83%

EPS (TTM)$-26.99

10-Day Avg Trading Volume0.21M

EPS Excl Extra (TTM)$-26.99

Revenue Growth (5Y)54.20%

EPS (Annual)$-8.43

ROI (Annual)-100.64%

Net Profit Margin (5Y Avg)-1199.06%

Cash / Share (Quarterly)$3.33

Revenue Growth QoQ (YoY)166.66%

ROA (Last FY)-63.02%

Revenue Growth TTM (YoY)354.37%

EBITD / Share (TTM)$-21.73

ROE (5Y Avg)-123.60%

Operating Margin (TTM)-262.03%

Cash Flow / Share (Annual)$-6.79

P/B Ratio52.55x

P/B Ratio (Quarterly)55.27x

Net Income / Employee (Annual)$-917,300

EV / Revenue (TTM)2.76x

ROA (TTM)-484.67%

EPS Incl Extra (Annual)$-8.43

Current Ratio (Annual)2.74x

Quick Ratio (Quarterly)1.16x

3-Month Avg Trading Volume0.23M

52-Week Price Return-29.49%

Revenue / Employee (TTM)$1,298,400

Tangible BV / Share (Quarterly)$1.95

P/S Ratio (Annual)4.42x

Asset Turnover (Annual)0.65x

52-Week High$45.50

Operating Margin (5Y Avg)-1208.72%

EPS Excl Extra (Annual)$-8.43

CapEx CAGR (5Y)-21.66%

Tangible BV CAGR (5Y)1.35%

26-Week Price Return27.17%

Quick Ratio (Annual)2.64x

13-Week Price Return-46.37%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.25x

Enterprise Value$104.00M

Revenue / Share Growth (5Y)139.76%

Asset Turnover (TTM)1.11x

Book Value / Share Growth (5Y)25.85%

Revenue / Employee (Annual)$947,100

Pretax Margin (Annual)-95.03%

Cash / Share (Annual)$8.43

3-Month Return Std Dev131.96%

Net Income / Employee (TTM)$-5,658,900

ROE (Last FY)-100.64%

EPS Basic Excl Extra (Annual)$-8.43

Receivables Turnover (TTM)12.74x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-26.99

Receivables Turnover (Annual)8.46x

ROI (TTM)-1006.12%

P/S Ratio (TTM)3.22x

Pretax Margin (5Y Avg)-1198.04%

Revenue / Share (Annual)$8.70

Tangible BV / Share (Annual)$3.69

Price vs S&P 500 (52W)-45.03%

Year-to-Date Return82.62%

5-Day Price Return-32.10%

EPS Normalized (Annual)$-8.43

ROA (5Y Avg)-76.57%

Net Profit Margin (Annual)-96.85%

Month-to-Date Return-35.41%

Cash Flow / Share (TTM)$-1.17

EBITD / Share (Annual)$-8.30

Operating Margin (Annual)-96.67%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-107.31%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-26.99

P/TBV (Quarterly)4.48x

P/B Ratio (Annual)1.05x

Pretax Margin (TTM)-434.50%

Book Value / Share (Annual)$8.21

Price vs S&P 500 (13W)-49.06%

Beta2.86x

Revenue / Share (TTM)$5.94

ROE (TTM)-1032.19%

52-Week Low$4.97

vGradeC

gGradeA

mGradeD

vgmGradeC

CUE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 14, 2026	-$1.69	-$24.14	-1328.40%(-$22.45)
Q1 2026	May 14, 2026	—	-$1.08	—
Q4 2025	Mar 16, 2026	-$2.70	$0.30	+111.11%(+$3.00)
Q3 2025	Nov 12, 2025	-$2.55	-$2.10	+17.65%(+$0.45)
Q2 2025	Aug 12, 2025	-$3.90	-$2.70	+30.77%(+$1.20)

CUE Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

4.17

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CUECue Biopharma, Inc.	C	A	D	3.2x	354.4%	—	—	$16.71
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Cue Biopharma, Inc.

Cue Biopharma is a clinical-stage biopharmaceutical company developing a proprietary class of biologics designed to selectively modulate the immune system for treating cancer and autoimmune diseases. The company's pipeline includes CUE-101 (alone and in combination with Pembrolizumab), CUE-102, CUE-103, and other candidates leveraging its immune modulation platform.

CUE Insider Transactions

SellOct 12, 2026
LIN SHAO-LEE
Chief Executive Officer
Shares: 11,087Value: $305,490
SellOct 12, 2026
RAY SUMITA J.D.
Officer
Shares: 1,844Value: $51,724
SellOct 12, 2026
MELUZIO MICHAEL VINCENT CPA
Officer
Shares: 1,144Value: $32,089
SellAug 13, 2026
LIN SHAO-LEE
Chief Executive Officer
Shares: 58,258Value: $1.61M
SellAug 13, 2026
RAY SUMITA J.D.
Officer
Shares: 8,829Value: $265,628

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for October 2026

Companies in Related Industries

ARMPArmata Pharmaceuticals, Inc. Common StockBiological Products
ABOSAcumen Pharmaceuticals, Inc. Common StockBiological Products
ACNTAscent Industries Co. Common StockChemicals
AVXLAnavex Life SciencesBiological Products
HUMAHumacyte, Inc. Common StockBiological Products
OTLKOutlook Therapeutics, Inc. Common StockBiological Products
VYGRVoyager Therapeutics, Inc. Common StockBiological Products
ENGNenGene Therapeutics Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Buy

Consensus rating

52-Week Range

Low$4.97

High$45.50